To investigate the association between semaglutide treatment and the risk of liver cirrhosis and hepatocellular carcinoma in individuals with type 2 diabetes.
Population-based cohort study design
Included adults with type 2 diabetes
Evaluated incidence of liver cirrhosis and hepatocellular carcinoma during treatment
Semaglutide treatment did not reduce the risk of liver cirrhosis
Semaglutide treatment was not linked to a lower incidence of hepatocellular carcinoma
Abstract
In this real-world study, semaglutide treatment was not associated with a reduced risk of liver cirrhosis or hepatocellular carcinoma among adults with type 2 diabetes mellitus.